Argiolas A, Mereu G, Serra G, Melis M R, Fadda F, Gessa G L
Brain Res. 1982 Jan 7;231(1):109-16. doi: 10.1016/0006-8993(82)90011-7.
N-n-propyl-norapomorphine (NPA) is 10-20 times more potent than apomorphine in producing hypomotility and inhibiting both striatal and limbic dopamine (DA) synthesis and the firing rate of nigral dopaminergic cells in rats. The threshold subcutaneous doses of NPA and apomorphine to significantly inhibit motor activity or DA synthesis are 1.25 and 24 microgram/kg, respectively. The intravenous ED 50 of NPA to inhibit dopaminergic firing is 0.36 microgram/kg and that for apomorphine is 9.1 microgram/kg. The above effects of NPA, as those of apomorphine, are antagonized by haloperidol and, stereospecifically by (--) sulpiride.
N-正丙基去甲阿扑吗啡(NPA)在使大鼠产生运动功能减退以及抑制纹状体和边缘系统多巴胺(DA)合成及黑质多巴胺能细胞放电频率方面,比阿扑吗啡强10至20倍。NPA和阿扑吗啡显著抑制运动活性或DA合成的阈皮下剂量分别为1.25和24微克/千克。NPA抑制多巴胺能放电的静脉注射半数有效量(ED50)为0.36微克/千克,阿扑吗啡的则为9.1微克/千克。NPA的上述作用,如同阿扑吗啡的作用一样,被氟哌啶醇拮抗,并且被(-)舒必利立体特异性拮抗。